MXPA06001195A - Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil. - Google Patents
Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil.Info
- Publication number
- MXPA06001195A MXPA06001195A MXPA06001195A MXPA06001195A MXPA06001195A MX PA06001195 A MXPA06001195 A MX PA06001195A MX PA06001195 A MXPA06001195 A MX PA06001195A MX PA06001195 A MXPA06001195 A MX PA06001195A MX PA06001195 A MXPA06001195 A MX PA06001195A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- metabolite
- inhibitor
- symptom
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invencion se refiere a un metabolito de un inhibidor de xantina fosfodiesterasa tipo 5 que tiene los siguientes derivados de estructura y formulaciones del mismo, y procedimientos para su preparacion; tambien se describen metodos para el tratamiento de un trastorno, sintoma o enfermedad fisiologico en un paciente, que comprende la administracion al paciente de una cantidad efectiva del siguiente compuesto (ver formula (I)) en donde el trastorno urogenital, cardiovascular, cerebrovascular o periferico vascular, angina de pecho, hipertension, restenosis despues de angioplastia, endarterectomia, introduccion de un stent, apoplejia cerebral, un trastorno del tracto respiratorio tal como una condicion alergica asociada con atopia, hipertension pulmonar, un trastorno cardiaco isquemico, alteracion de la tolerancia a la glucosa, diabetes o su complicacion relacionada, sindrome de resistencia a la insulina, hiperglicemia, sindrome de ovario policistico, un trastorno glomerular, insuficiencia renal, nefritis, un trastorno intersticial tubular, un trastorno autoinmune, glaucoma, motilidad intestinal, caquexia o cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49221803P | 2003-07-31 | 2003-07-31 | |
| PCT/US2004/024525 WO2005012303A1 (en) | 2003-07-31 | 2004-07-29 | Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06001195A true MXPA06001195A (es) | 2006-04-11 |
Family
ID=34115611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06001195A MXPA06001195A (es) | 2003-07-31 | 2004-07-29 | Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7312223B2 (es) |
| EP (1) | EP1648895B1 (es) |
| JP (1) | JP2007500714A (es) |
| CN (1) | CN1860119A (es) |
| AT (1) | ATE363483T1 (es) |
| CA (1) | CA2533715A1 (es) |
| DE (1) | DE602004006756T2 (es) |
| ES (1) | ES2284056T3 (es) |
| HK (1) | HK1082739A1 (es) |
| MX (1) | MXPA06001195A (es) |
| WO (1) | WO2005012303A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| DK1509525T5 (da) * | 2002-05-31 | 2007-07-30 | Schering Corp | Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor |
| CA2577442A1 (en) * | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
| KR20090087795A (ko) * | 2008-02-13 | 2009-08-18 | 한양대학교 산학협력단 | 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트 |
| CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| US20100261737A1 (en) * | 2009-04-10 | 2010-10-14 | Medtronic Vascular, Inc. | Method of Treating Erectile Dysfunction |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US20140328893A1 (en) | 2011-10-11 | 2014-11-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nutlin compounds for use in the treatment of pulmonary hypertension |
| CN106770618A (zh) * | 2015-11-20 | 2017-05-31 | 中国康复研究中心 | 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| ZA914727B (en) * | 1990-06-21 | 1992-03-25 | Schering Corp | Polycyclic guanine derivatives |
| GB9020959D0 (en) * | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
| EP0563168B1 (en) * | 1990-12-21 | 2000-07-05 | Beecham Group Plc | Xanthine derivatives |
| GB9210839D0 (en) | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
| AU681875B2 (en) * | 1993-02-26 | 1997-09-11 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
| US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| DK1509525T5 (da) * | 2002-05-31 | 2007-07-30 | Schering Corp | Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor |
| ES2299720T3 (es) * | 2002-05-31 | 2008-06-01 | Schering Corporation | Formas polimorfas de un inhibidor de xantina-fosfodiesterasa v. |
-
2004
- 2004-07-29 ES ES04779540T patent/ES2284056T3/es not_active Expired - Lifetime
- 2004-07-29 CA CA002533715A patent/CA2533715A1/en not_active Abandoned
- 2004-07-29 EP EP04779540A patent/EP1648895B1/en not_active Expired - Lifetime
- 2004-07-29 JP JP2006522068A patent/JP2007500714A/ja active Pending
- 2004-07-29 WO PCT/US2004/024525 patent/WO2005012303A1/en active IP Right Grant
- 2004-07-29 DE DE602004006756T patent/DE602004006756T2/de not_active Expired - Fee Related
- 2004-07-29 US US10/901,574 patent/US7312223B2/en not_active Expired - Fee Related
- 2004-07-29 CN CNA2004800280878A patent/CN1860119A/zh active Pending
- 2004-07-29 MX MXPA06001195A patent/MXPA06001195A/es active IP Right Grant
- 2004-07-29 AT AT04779540T patent/ATE363483T1/de not_active IP Right Cessation
-
2006
- 2006-05-03 HK HK06105215A patent/HK1082739A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1082739A1 (en) | 2006-06-16 |
| EP1648895A1 (en) | 2006-04-26 |
| ATE363483T1 (de) | 2007-06-15 |
| EP1648895B1 (en) | 2007-05-30 |
| ES2284056T3 (es) | 2007-11-01 |
| WO2005012303A1 (en) | 2005-02-10 |
| CA2533715A1 (en) | 2005-02-10 |
| DE602004006756T2 (de) | 2008-01-24 |
| US7312223B2 (en) | 2007-12-25 |
| US20050026939A1 (en) | 2005-02-03 |
| CN1860119A (zh) | 2006-11-08 |
| JP2007500714A (ja) | 2007-01-18 |
| DE602004006756D1 (de) | 2007-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1082739A1 (en) | Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment oferectile dysfunction | |
| DE60019919T2 (de) | Hydrochloride kondensierter heterozyklen | |
| RU2009114857A (ru) | Гетероциклические органические соединения | |
| JP2010511727A5 (es) | ||
| CN108697807A (zh) | 代谢功能障碍引起的肿瘤的治疗 | |
| JP2010511727A (ja) | アデノシン受容体アンタゴニストとしての置換ピリミジン | |
| JP2004500425A (ja) | パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用 | |
| JP2018505859A5 (es) | ||
| JP2015007096A (ja) | 運動障害の予防および／または治療剤 | |
| JP2016523243A5 (es) | ||
| JP2019513126A5 (es) | ||
| WO2008002902A3 (en) | Adenosine a2b receptor antagonists | |
| IL263412B (en) | Treatment methods for Freder Willi syndrome | |
| NZ597222A (en) | Substituted 8-[6-Amino-3-Pyridyl]Xanthines | |
| JP2024534580A (ja) | 代謝障害を処置する方法 | |
| JP2007500714A5 (es) | ||
| Zuo et al. | Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists | |
| YU12003A (sh) | Novi derivati aminocikloheksana | |
| Druzhilov et al. | Promising areas of pharmacotherapy for obesity | |
| EP2094285B1 (de) | Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp) | |
| Berk et al. | New 8-substituted xanthiene derivatives as potent bronchodilators | |
| JPH0273015A (ja) | 置換３，４‐ジヒドロ‐２ｈ‐ベンゾピラン類の肺の閉鎖性機能障害および／または輸出尿路の障害の治療薬としての使用 | |
| Boss | 20 Years of Medicinal Chemistry–Always Look at the Bright Side (of Life) | |
| Ran et al. | Scaffold-based design of xanthine as highly potent inhibitors of DPP-IV for improving glucose homeostasis in DIO mice | |
| CN111393442A (zh) | 黄嘌呤类衍生物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |